Dystrophin mutations predict cellular susceptibility to oxidative stress

Mutations in the dystrophin gene that lead to the expression of truncated forms of the dystrophin protein cause muscular dystrophies of varying severities both in humans and in mice. We have shown previously that dystrophin‐deficient muscle is more susceptible to oxidative injury than is normal muscle. In this report, we have used muscle cells derived from mdx mice, which express no dystrophin, and mdx‐transgenic strains that express full‐length dystrophin or truncated forms of dystrophin to explore further the relationship between dystrophin expression and susceptibility of muscle to oxidative injury. We show that, when differentiated into myotubes, the relative susceptibility of the cell populations to oxidative stress correlates with the severity of the dystrophy in the strain from which the cells were isolated. The most susceptible populations exhibited the greatest oxidative damage as assessed by protein oxidation. Thus, the relative efficacy of truncated dystrophin proteins to protect muscle from necrotic degeneration in vivo is predicted by their ability to protect muscle cells from free radical mediated injury. These findings support the hypothesis that the dystrophin protein complex may have important regulatory or signaling properties in terms of cell survival and antioxidant defense mechanisms. © 2000 John Wiley & Sons, Inc. Muscle Nerve 23: 784–792, 2000

[1]  T. Rando,et al.  Integrin-mediated Muscle Cell Spreading , 1999, The Journal of Biological Chemistry.

[2]  T. Rando,et al.  Regulation of antioxidant enzyme gene expression in response to oxidative stress and during differentiation of mouse skeletal muscle. , 1999, Free radical biology & medicine.

[3]  C. Epstein,et al.  Copper/zinc superoxide dismutase: More is not necessarily better! , 1999, Annals of neurology.

[4]  S. Carbonetto,et al.  α-Dystroglycan Is a Laminin Receptor Involved in Extracellular Matrix Assembly on Myotubes and Muscle Cell Viability , 1999, The Journal of cell biology.

[5]  N. Hattori,et al.  Undetectable dystrophin can still result in a relatively benign phenotype of dystrophinopathy , 1999, Neuromuscular Disorders.

[6]  S. Froehner,et al.  A PDZ-containing Scaffold Related to the Dystrophin Complex at the Basolateral Membrane of Epithelial Cells , 1999, The Journal of cell biology.

[7]  G. Macchia,et al.  Association of the Dystroglycan Complex Isolated from Bovine Brain Synaptosomes with Proteins Involved in Signal Transduction , 1999, Journal of neurochemistry.

[8]  I. Nonaka,et al.  α1-Syntrophin Gene Disruption Results in the Absence of Neuronal-type Nitric-oxide Synthase at the Sarcolemma but Does Not Induce Muscle Degeneration* , 1999, The Journal of Biological Chemistry.

[9]  K. Campbell,et al.  Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction. , 1999, Journal of cell science.

[10]  P. Huang,et al.  Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  I. Hausmanowa-Petrusewicz,et al.  A dystrophin missense mutation showing persistence of dystrophin and dystrophin‐associated proteins yet a severe phenotype , 1998, Annals of neurology.

[12]  M. Beal,et al.  Evidence of oxidative stress in mdx mouse muscle: Studies of the pre-necrotic state , 1998, Journal of the Neurological Sciences.

[13]  D. Taverna,et al.  Dystrophic Muscle in Mice Chimeric for Expression of α5 Integrin , 1998, The Journal of cell biology.

[14]  R. Wollmann,et al.  γ-Sarcoglycan Deficiency Leads to Muscle Membrane Defects and Apoptosis Independent of Dystrophin , 1998, The Journal of cell biology.

[15]  C. Epstein,et al.  Overexpression of copper/zinc superoxide dismutase: A novel cause of murine muscular dystrophy , 1998, Annals of neurology.

[16]  D. Wink,et al.  Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.

[17]  D. Bredt,et al.  Muscular Dystrophy in mdx Mice Despite Lack of Neuronal Nitric Oxide Synthase , 1998, Journal of neurochemistry.

[18]  K. Campbell,et al.  mdx muscle pathology is independent of nNOS perturbation. , 1998, Human molecular genetics.

[19]  E. Hoffman,et al.  Mutations in the integrin α7 gene cause congenital myopathy , 1998, Nature Genetics.

[20]  J. Stull,et al.  Sparing of mdx extraocular muscles from dystrophic pathology is not attributable to normalized concentration or distribution of neuronal nitric oxide synthase , 1998, Neuromuscular Disorders.

[21]  T. Rando,et al.  Muscle cells from mdx mice have an increased susceptibility to oxidative stress , 1998, Neuromuscular Disorders.

[22]  M. Shigekawa,et al.  Bidirectional Signaling between Sarcoglycans and the Integrin Adhesion System in Cultured L6 Myocytes* , 1998, The Journal of Biological Chemistry.

[23]  R. Fässler,et al.  Absence of integrin α7 causes a novel form of muscular dystrophy , 1997, Nature Genetics.

[24]  J. D. Porter,et al.  Oxidative stress as a potential pathogenic mechanism in an animal model of Duchenne muscular dystrophy , 1997, Neuromuscular Disorders.

[25]  K. Campbell,et al.  Muscular dystrophies and the dystrophin-glycoprotein complex. , 1997, Current opinion in neurology.

[26]  J. Haycock,et al.  Oxidative damage to muscle protein in Duchenne muscular dystrophy , 1996, Neuroreport.

[27]  J. Stull,et al.  Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Bredt,et al.  Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy , 1996, The Journal of experimental medicine.

[29]  M. Jackson,et al.  How does dystrophin deficiency lead to muscle degeneration? — Evidence from the MDX mouse , 1995, Neuromuscular Disorders.

[30]  K. Widhalm,et al.  Oxyradical damage and mitochondrial enzyme activities in the mdx mouse. , 1995, Neuropediatrics.

[31]  K. Aldape,et al.  Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy , 1995, Cell.

[32]  J. Faulkner,et al.  Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. , 1995, Human molecular genetics.

[33]  S. Lipton,et al.  Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  John Calvin Reed,et al.  The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Tidball,et al.  Apoptosis precedes necrosis of dystrophin-deficient muscle. , 1995, Journal of cell science.

[36]  K. Campbell,et al.  Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice , 1994, Nature Genetics.

[37]  K. Campbell,et al.  Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy , 1994, Nature Genetics.

[38]  K. Campbell,et al.  Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. , 1994, Human molecular genetics.

[39]  H. Blau,et al.  Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy , 1994, The Journal of cell biology.

[40]  M. Passos-Bueno,et al.  Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. , 1994, Human molecular genetics.

[41]  E. Stadtman,et al.  Carbonyl assays for determination of oxidatively modified proteins. , 1994, Methods in enzymology.

[42]  M. Schwartz,et al.  The extracellular matrix as a cell survival factor. , 1993, Molecular biology of the cell.

[43]  K. Campbell,et al.  Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity , 1993, Nature.

[44]  J. Mendell,et al.  Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy , 1993 .

[45]  L. Kunkel,et al.  The structural and functional diversity of dystrophin , 1993, Nature Genetics.

[46]  M. Schwartz Transmembrane signalling by integrins. , 1992, Trends in cell biology.

[47]  K. Davies,et al.  Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. , 1992, Human molecular genetics.

[48]  K. Campbell,et al.  Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice , 1991, The Journal of cell biology.

[49]  P. Walker Ischemia/reperfusion injury in skeletal muscle , 1991, Annals of vascular surgery.

[50]  J. D. Young,et al.  Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. , 1991, Journal of immunology.

[51]  K. Davies,et al.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.

[52]  B. Halliwell,et al.  Role of free radicals and catalytic metal ions in human disease: an overview. , 1990, Methods in enzymology.

[53]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[54]  J P Kehrer,et al.  Oxidative stress and muscular dystrophy. , 1989, Chemico-biological interactions.

[55]  M. W. Thompson,et al.  Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. , 1988, Science.

[56]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[57]  K. Moore,et al.  X chromosome-linked muscular dystrophy (mdx) in the mouse. , 1984, Proceedings of the National Academy of Sciences of the United States of America.